

Resource Summary Report

Generated by [dkNET](#) on Sep 5, 2026

L-363

RRID:CVCL_1357

Type: Cell Line

Proper Citation

RRID:CVCL_1357

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1357

Proper Citation: RRID:CVCL_1357

Description: Cell line L-363 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Plasma cell myeloma

Defining Citation: [PMID:207377](#), [PMID:2537114](#), [PMID:10087940](#), [PMID:10583232](#), [PMID:10936422](#), [PMID:11157491](#), [PMID:15215163](#), [PMID:16956823](#), [PMID:17692805](#), [PMID:18647998](#), [PMID:20164919](#), [PMID:21173094](#), [PMID:22460905](#), [PMID:23074853](#), [PMID:25485619](#), [PMID:25688540](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30285677](#), [PMID:30545397](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:32123307](#), [PMID:35839778](#)

Comments: Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck, Catherine., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: L-363

Synonyms: L 363, L363

Cross References: BTO:BTO_0003308, CLO:CLO_0007186, EFO:EFO_0006450, CLDB:cl3080, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-

MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ArrayExpress:E-TABM-937, BioGRID_ORCS_Cell_line:923, BioSample:SAMN03472932, BioSample:SAMN10988577, cancercellines:CVCL_1357, Cell_Model_Passport:SIDM00312, CGH-DB:9157-4, ChEMBL-Cells:ChEMBL3308205, ChEMBL-Targets:ChEMBL2366267, Cosmic:720779, Cosmic:924239, Cosmic:1889517, Cosmic:2081396, Cosmic:2367279, Cosmic:2809755, Cosmic-CLP:924239, DepMap:ACH-000183, DSMZ:ACC-49, DSMZCellDive:ACC-49, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002414, EGA:EGAS00001002554, GDSC:924239, GEO:GSM887259, GEO:GSM888334, GEO:GSM1374615, GEO:GSM1670028, IARC_TP53:27175, LiGeA:CCL_630, LINCS_LDP:LCL-2045, Lonza:1421, PharmacDB:L363_814_2019, PRIDE:PXD030304, Progenetix:CVCL_1357, PubChem_Cell_line:CVCL_1357, Wikidata:Q54900864

ID: CVCL_1357

Record Creation Time: 20220427T220712+0000

Record Last Update: 20260904T014520+0000

Ratings and Alerts

No rating or validation information has been found for L-363.

No alerts have been found for L-363.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Tiwari PK, et al. (2026) An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma. Cell reports, 45(6), 117464.

Tang A, et al. (2026) Targeting BCMA in multiple myeloma with a trifunctional NK cell engager. Cell reports. Medicine, 7(3), 102628.

Cholujova D, et al. (2026) Anti-myeloma activity of the CXCR4 antagonist WZ811. Journal of molecular medicine (Berlin, Germany), 104(1), 45.

Jiang K, et al. (2026) The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma. Molecular cancer therapeutics, 25(6), 1016.

Lesire L, et al. (2026) Enhancing antitumour response to proteasome inhibitors with inhibitors of insulin-degrading enzyme, a new molecular vulnerability in multiple myeloma. British journal of pharmacology, 183(12), 3355.

Ben Hamza A, et al. (2024) Virus-reactive T cells expanded in aplastic anemia eliminate hematopoietic progenitor cells by molecular mimicry. *Blood*, 143(14), 1365.

Bolomsky A, et al. (2024) IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. *Cancer cell*, 42(7), 1185.

Shearer T, et al. (2024) Kinetics of Nirogacestat-Mediated Increases in B-cell Maturation Antigen on Plasma Cells Inform Therapeutic Combinations in Multiple Myeloma. *Cancer research communications*, 4(12), 3114.

Heredia-Guerrero SC, et al. (2024) Functional Investigation of IGF1R Mutations in Multiple Myeloma. *Cancers*, 16(11).

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. *Cell chemical biology*, 31(7), 1247.

Lepore A, et al. (2023) An Integrated Methodology to Quantify the Glycolytic Stress in Plasma Cell Myeloma in Response to Cytotoxic Drugs. *Methods in molecular biology* (Clifton, N.J.), 2675, 285.

Mondala PK, et al. (2021) Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption. *Cell stem cell*, 28(4), 623.

Vannam R, et al. (2021) Targeted degradation of the enhancer lysine acetyltransferases CBP and p300. *Cell chemical biology*, 28(4), 503.

Shirasaki R, et al. (2021) Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degradable Oncoproteins. *Cell reports*, 34(1), 108532.